IRIS
RUZZO, ANNAMARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.745
EU - Europa 6.648
AS - Asia 2.497
OC - Oceania 35
Continente sconosciuto - Info sul continente non disponibili 16
AF - Africa 15
SA - Sud America 15
AN - Antartide 1
Totale 19.972
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.698
GB - Regno Unito 2.462
CN - Cina 1.846
UA - Ucraina 1.211
IT - Italia 722
SE - Svezia 491
FR - Francia 490
TR - Turchia 427
FI - Finlandia 369
DE - Germania 361
IE - Irlanda 239
PL - Polonia 96
RU - Federazione Russa 69
AT - Austria 62
IN - India 62
KR - Corea 58
CA - Canada 40
AU - Australia 31
BE - Belgio 23
NL - Olanda 20
EU - Europa 15
IR - Iran 15
JP - Giappone 14
PK - Pakistan 11
SG - Singapore 9
HK - Hong Kong 8
RO - Romania 8
VN - Vietnam 8
TG - Togo 7
BG - Bulgaria 6
BR - Brasile 6
SA - Arabia Saudita 5
BD - Bangladesh 4
EC - Ecuador 4
ID - Indonesia 4
MX - Messico 4
NZ - Nuova Zelanda 4
ES - Italia 3
GR - Grecia 3
IQ - Iraq 3
LK - Sri Lanka 3
TH - Thailandia 3
AE - Emirati Arabi Uniti 2
BH - Bahrain 2
CH - Svizzera 2
CL - Cile 2
DK - Danimarca 2
HU - Ungheria 2
MA - Marocco 2
MO - Macao, regione amministrativa speciale della Cina 2
PA - Panama 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
TW - Taiwan 2
ZA - Sudafrica 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
AR - Argentina 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
CU - Cuba 1
CY - Cipro 1
CZ - Repubblica Ceca 1
EG - Egitto 1
GS - Georgia del Sud e Isole Sandwich Australi 1
JO - Giordania 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
MK - Macedonia 1
MY - Malesia 1
NG - Nigeria 1
PE - Perù 1
PH - Filippine 1
SI - Slovenia 1
Totale 19.972
Salva come PNG Salva come JPEG
Città #
Southend 2.282
Fairfield 1.666
Woodbridge 1.292
Houston 1.156
Jacksonville 970
Ashburn 823
Seattle 713
Ann Arbor 679
Cambridge 671
Wilmington 646
Nanjing 611
Chandler 517
Izmir 401
Dublin 239
Nanchang 216
Beijing 167
Princeton 145
Helsinki 143
Bremen 135
New York 110
Shenyang 105
San Mateo 102
Tianjin 99
Kunming 98
Hebei 91
Kraków 90
Urbino 79
San Diego 67
Boardman 66
Jiaxing 66
Changsha 62
Düsseldorf 62
Vienna 61
Hangzhou 48
Seongnam 45
Velikiy Novgorod 42
London 34
San Francisco 34
Jinan 33
Falls Church 29
Toronto 28
Ningbo 27
Lanzhou 26
Changchun 24
Shanghai 24
Strasbourg 23
Dearborn 20
Brussels 17
Zhengzhou 17
Munich 16
Mülheim 16
Redwood City 15
Rome 15
Acton 13
Guangzhou 13
Los Angeles 13
Melbourne 12
Norwalk 12
Taizhou 12
Ancona 11
Bisceglie 11
Cesena 10
Indiana 10
Kocaeli 10
Auburn Hills 9
Cagliari 9
Canberra 9
Fuzhou 9
Milan 9
Multan 9
Turin 9
Augusta 8
Chicago 8
Monterotondo 8
Des Moines 7
Fano 7
Haikou 7
Hefei 7
Lomé 7
Portland 7
Seoul 7
Tappahannock 7
Bangalore 6
Paris 6
Perugia 6
Saint Petersburg 6
Tokyo 6
Tortolì 6
Wuhan 6
Bologna 5
Chiswick 5
Civitanova Marche 5
Kilburn 5
Mumbai 5
Napoli 5
Orange 5
Pesaro 5
Prescot 5
Riyadh 5
Sundbyberg 5
Totale 15.530
Salva come PNG Salva come JPEG
Nome #
TS, MTHFR AND XRCC1 GENETIC VARIANTS INFLUENCE THE OUTCOME OF MDS PATIENTS IRRESPECTIVELY OF IPSS RISK 259
XRCC1 399GG genotype predicts significantly longer overall survival in resistant lymphoma patients treated with Benda-EAM and ASCT 258
2196 Polymorphisms and miRNAs targeting CLOCK gene affect gender-related survival in metastatic colorectal cancer (mCRC) patients (pts) 251
VEGF gene polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) 227
C-MET gene copy number variation (CNV) analysis by quantitative PCR (qPCR) assay in Caucasian patients with gastric cancer (GC). 222
The Mutational Status Of Genes Involved In DNA Repair and Folate Pathway Predicts Overall Survival Of Patients With Low-Risk, Untreated Myelodysplastic Syndrome 220
Dihydropyrimidine dehydrogenase (DPYD) gene polymorphisms profiling in colon cancer patients treated with adjuvant chemotherapy in the randomized phase III TOSCA trial 219
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients 216
VEGF GENE POLYMORPHISMS IN THE PREDICTION OF BENEFIT FROM FIRST-LINE FOLFIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) 207
BRAF V600E mutation and Amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients 200
Clinical impact of the HGF/MET pathway activation in patients with advanced gastric cancer treated with palliative chemotherapy 198
Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status. 191
Evaluation of MET using FISH, IHC, or mass spectrometry as a prognostic biomarker in patients with gastroesophageal cancer 190
Endogastric capsule for E-cadherin gene (CDH1) promoter hypermethylation assessment in DNA from gastric juice of diffuse gastric cancer patients. 188
Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients 188
Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy 187
Glucose metabolism enzymes gene expression analysis and selective metabolic advantage in the progression of colorectal cancer (CRC) 186
Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes 185
Gender effects of single nucleotide polymorphisms and miRNAs targeting clock-genes in metastatic colorectal cancer patients (mCRC) 185
Structure of the human hexokinase type I gene and nucleotide sequence of the 5' flanking region 183
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. 183
Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients 182
Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan 181
The genotype of a new linked DNA marker, MP6d-9, is related to the clinicalcourse of cystic fibrosis. 178
MET as a prognostic biomarker of survival in a large cohort of patients with gastroesophageal cancer (GEC) 178
Genetic modulation of the Interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy 176
MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine 175
NOD2/CARD15 polymorphisms impair innate immunity and increase susceptibility to gastric cancer in an Italian population 174
Effect of polymorphisms and miRNAs targeting CLOCK gene on gender-related survival in metastatic colorectal cancer (mCRC) patients (pts). 174
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. 173
Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype. 171
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer 170
Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. 168
Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy 168
Emerging biomarkers in bladder cancer identified by network analysis of transcriptomic data 167
The G/A Nucleotide Change at cDNA Position 2494 in the E-Cadherin Gene (CDH1): Analysis in Italian Patients 166
Molecular analysis of G6PD variants in northern Italy: a study on the population from the Ferrara district. 166
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy 163
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. 163
BRAF V600E MUTATION AND AMPHIREGULIN (AR) IMMUNOHISTOCHEMICAL EXPRESSION IN THE PREDICTION OF BENEFIT FROM CETUXIMAB PLUS IRINOTECAN IN KRAS WILD-TYPE METASTATIC COLORECTAL CANCER (mCRC) PATIENTS 163
Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"? 162
VEGF gene polymorphisms and susceptibility to colorectal cancer disease in italian population 161
Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer 161
Glucose metabolism enzymes gene expression analysis and selective metabolism advantage in the clinical progression of colorectal cancer (CRC) 161
High resolution melting (HRM) analysis for the detection of ER22/23EK, BclI, and N363S polymorphisms of the glucocorticoid receptor gene. 160
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. 159
Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer 159
Evaluation of Period 2 gene (PER-2) biologic profile in advanced colorectal cancer (ACC) patients treated with chronomodulated chemotherapy 159
An erythroid-specific exon is present in the human hexokinase gene 157
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy 157
Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer. 156
Molecular analysis of G6PD variants in northern Italy: a study on the population from the Ferrara district 154
Prognostic Impact of TS, MTHFR and XRCC1 Genetic Variants in 113 Patients with Myelodysplastic Syndromes 154
PTEN EXPRESSION AND KRAS MUTATIONS AS PREDICTORS OF BENEFIT FROM CETUXIMAB PLUS IRINOTECAN (CETIRI) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) 153
Author Correction: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition 153
Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients 153
High Let-7a MicroRNA Levels in KRAS-Mutated Colorectal Carcinomas May Rescue Anti-EGFR Therapy Effects in Patients with Chemotherapy-Refractory Metastatic Disease 152
Assignment of the hexokinase type 3 gene (HK3) to human chromosome band 5q35.3 by somatic cell hybrids and in situ hybridization 150
Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer 149
Association of Thymidylate Synthase Polymorphisms with Gastric Cancer Susceptibility 149
A Novel Homozygous Variant in the Fork-Head-Associated Domain of Polynucleotide Kinase Phosphatase in a Patient Affected by Late-Onset Ataxia With Oculomotor Apraxia Type 4 149
Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer 146
Structure of the 5' region of the human hexokinase type I (HKI) gene and identification of an additional testis-specific HKI mRNA 144
High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice 143
PHARMACOGENETIC PROFILING FOR TOXICITY OF OXALIPLATIN AND FLUOROPYRIMIDINES. FINAL REPORT FROM AN ANCILLARY PROTOCOL TO THE TOSCA TRIAL 143
Hexokinase 142
K-RAS STATUS IN PRIMARY COLORECTAL TUMOURS CORRELATE WITH K-RAS STATUS IN RELATED METASTATIC SITES: IMPLICATIONS FOR TREATMENT WITH ANTI-EGFR ANTIBODIES IN CLINICAL SETTING 141
Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs 140
Predictive and prognostic role of E-cadherin expression in patients with advanced gastric cancer treated with palliative chemotherapy. 140
High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice 139
XRCC1 399GG GENOTYPE PREDICTS SIGNIFICANTLY LONGER OVERALL SURVIVAL AND LONG LASTING CR IN RESISTANT LYMPHOMA TREATED WITH BENDA-BEAM AND ASCT 139
Structure of the human hexokinase type I gene. 139
Prognostic role of thymidylate synthase polymorphisms in gastric cancer patientstreated with surgery and adjuvant chemotherapy. 138
Methylenetetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at-risk italian population 137
Glucose-6-phosphate dehydrogenase nucleotide 1311 polymorphism in central Italy(Marche Region). 137
Period 2 (PER-2) biologic profile in advanced colorectal cancer (ACC) patients (pts) 136
Let-7a microRNA levels in KRAS-mutated colorectal carcinomas determine survival differences in patients treated with anti-EGFR 136
Linkage disequilibrium for DNA haplotypes near the cystic fibrosis locus in twosouth European populations 135
Predictive and Prognostic Role of E-Cadherin Protein Expression in Patients with Advanced Gastric Carcinomas Treated with Palliative Chemotherapy 134
Sex-Related Differences in Impact On Safety Of Pharmacogenetic Profile For Colon Cancer Patients Treated With FOLFOX-4 or XELOX Adjuvant Chemotherapy 134
Amplificazione enzimatica specifica di una regione di DNA strettamente associata alla Corea di Huntington 133
Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients 133
TS, MTHFR AND XRCC1 GENETIC VARIANTS AFFECT THE CLINICAL COURSE OF MDS PATIENTS IRRESPECTIVELY OF IPSS RISK 133
Prognostic Analysis of E-Cadherin Gene Promoter Hypermethylation in Patients with Surgically Resected, Node-Positive, Diffuse Gastric Cancer 133
MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma 132
Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy 131
Molecular basis of the 2',3'-dideoxycytidine induced drug-resistance in human cells 130
Germline variants and clinical outcomes of high-risk stage II and stage III colon cancer patients treated with oxaliplatin and fluoropyrimidines adjuvant chemotherapy: a pharmacogenetic ancillary study to TOSCA trial 130
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer 129
Pharmacogenetic profiling for toxicity of oxaliplatin and fluoripyrimidines. An Ancillary protocol to the TOSCA trial 129
Prognostic role of thymidylate synthase (TS) gene polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. 129
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomized, phase III adjuvant TOSCA trial in high-risk colon cancer patients. 129
THE EXPRESSION OF THE KRAS mRNA ISOFORMS 4A AND 4B IN PLASMA: A COMPARISON BETWEEN LUNG ADENOCARCINOMA PATIENTS AND HEALTHY DONORS THROUGH LIQUID BIOPSY 127
TP53 mutation analysis in gastric cancer and clinical outcomes of patients with metastatic disease treated with Ramucirumab-Paclitaxel or standard chemotherapy 124
Identification of seven novel germline mutations in the human E-cadherin (CDH1) gene. 123
HOST GENETIC VARIANTS IN THE INSULIN GROWTH FACTOR BINDING PROTEIN-3 IMPACT ON SURVIVAL OF PATIENTS WITH ADVANCED GASTRIC CANCER TREATED WITH PALLIATIVE CHEMOTHERAPY 123
PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients. 122
Reply: KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity? 121
Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer 120
BRAF mutations and EGFR Intron-1 L/L genotype are associated with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients 119
Totale 16.060
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.919
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.919
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.213 0 0 0 0 0 0 0 0 0 0 400 813
2019/20205.119 872 225 401 1.175 266 390 481 401 288 294 151 175
2020/20212.900 117 261 282 245 247 220 285 201 372 225 351 94
2021/20221.760 116 189 211 225 82 69 76 96 107 84 81 424
2022/20231.964 289 78 22 201 254 415 7 103 362 70 97 66
2023/2024586 69 52 33 46 82 166 26 45 9 58 0 0
Totale 20.251